Chongqing Precision Biotech Co., Ltd is advancing its C-13-60 CAR-T cell therapy targeting CEA-positive advanced malignant solid tumors through a Phase I clinical trial. The trial aims to establish safety, tolerability, and pharmacokinetics while preliminarily assessing efficacy. The targeted patient population includes those with advanced colorectal, esophageal, gastric, pancreatic, non-small cell lung, breast, and cholangiocarcinoma who have exhausted standard treatment options. The success of this trial could position C-13-60 as a novel therapeutic option in a competitive landscape dominated by existing CAR-T therapies and immune checkpoint inhibitors. Given the high unmet need in these indications, particularly in late-stage cancers, there is significant market potential if the therapy demonstrates favorable outcomes. The trial's recruitment status is currently active, with an estimated completion date in 2027, indicating a long-term investment horizon for stakeholders.